Literature DB >> 21172182

Aberrant gastric apomucin expression in ulcerative colitis and associated neoplasia.

Paula Borralho1, Ana Vieira, João Freitas, Paula Chaves, Jorge Soares.   

Abstract

AIM: To evaluated the presence of gastric metaplasia in colonic mucosa of patients with ulcerative colitis and its relationship with dysplasia/neoplasia.
MATERIAL AND METHODS: Ninety patients with UC were selected. The duration and the extent of disease were registered in all the cases. Biopsies were histologically and immunohistochemically assessed. Crypt distortion, goblet cell depletion, Paneth cell metaplasia and inflammatory activity were graded, as well as dysplasia and invasive neoplasia (absent or present). Monoclonal antibodies against the gastric apomucins MUC5AC (foveolar) and MUC6 (mucopeptic) were used.
RESULTS: Neoplasia was observed in 16 patients, 8 non-invasive (dysplasia) and 8 invasive (adenocarcinoma). MUC5AC and MUC6 were detected in 63 and 16 out the 90 cases, 70.0% and 17.8%, respectively. The staining was patchy for both antibodies, affecting groups of cells more often than isolated cells. The presence of MUC5AC correlated positively with inflammatory activity and goblet cell depletion (R=0.231, p=0.03 and R=0.211, p=0.048, respectively). The expression of MUC6 correlated positively with age (R=0.297, p=0.005), duration of disease (R=0.287, p=0.008), extent of disease (R=0.342, p=0.001), crypt distortion (R=0.276, p=0.01) and the presence of neoplasia (R=0.483, p<0.00). There was no correlation between Paneth cell metaplasia and apomucin expression.
CONCLUSIONS: Our study demonstrates the aberrant expression of gastric apomucins in UC and suggests that MUC5AC is associated with inflammation while MUC6 is related to the presence of neoplasia. The demonstration of metaplastic cell lineages preceding dysplasia supports the biological link between inflammation and neoplasia, MUC6 emerging as a putative biomarker of dysplasia in ulcerative colitis patients.

Entities:  

Year:  2007        PMID: 21172182     DOI: 10.1016/j.crohns.2007.06.006

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

Review 1.  Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.

Authors:  Shiv Ram Krishn; Koelina Ganguly; Sukhwinder Kaur; Surinder K Batra
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

2.  Muc5ac Expression Protects the Colonic Barrier in Experimental Colitis.

Authors:  Kristine E Olli; Caroline Rapp; Lauren O'Connell; Colm B Collins; Eoin N McNamee; Owen Jensen; Paul Jedlicka; Kristen C Allison; Matthew S Goldberg; Mark E Gerich; Daniel N Frank; Diana Ir; Charles E Robertson; Christopher M Evans; Carol M Aherne
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

3.  Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus.

Authors:  Tsutomu Mizoshita; Satoshi Tanida; Hironobu Tsukamoto; Keiji Ozeki; Takahito Katano; Masahide Ebi; Yoshinori Mori; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  ISRN Gastroenterol       Date:  2013-04-09

4.  Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.

Authors:  Tsutomu Mizoshita; Satoshi Tanida; Hironobu Tsukamoto; Keiji Ozeki; Takahito Katano; Hirotaka Nishiwaki; Masahide Ebi; Yoshinori Mori; Eiji Kubota; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Gastroenterol Res Pract       Date:  2014-04-16       Impact factor: 2.260

5.  Retinoid acid induced 16 deficiency aggravates colitis and colitis-associated tumorigenesis in mice.

Authors:  Yu-Lin Xu; Cui-Ling Ding; Chun-Lin Qian; Zhong-Tian Qi; Wen Wang
Journal:  Cell Death Dis       Date:  2019-12-20       Impact factor: 8.469

6.  Loss of Nckx3 Exacerbates Experimental DSS-Induced Colitis in Mice through p53/NF-κB Pathway.

Authors:  Dinh Nam Tran; Seon Myeong Go; Seon-Mi Park; Eui-Man Jung; Eui-Bae Jeung
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.